The use of central venous catheters, while advantageous, is associated with a range of complications including thrombosis and infection. These complications can pose significant physical and financial costs to the patient and health care system. A critical appraisal of the two randomized controlled trials examining this topic in critically ill patients has shown that heparin-bonded central venous catheters significantly reduced the incidence of catheterrelated thrombosis and infection in children and adults. These findings suggest that heparin-bonded central venous catheters should be considered for routine use in critically ill patients.
CLInICAL SCEnArIo
In the acute hospital setting, patients may need a central venous catheter (CVC) for a variety of reasons, including delivery of critical medications and parenteral nutrition, renal replacement therapy, blood sampling and/or central venous monitoring. unfortunately, CVC use is associated with a range of complications including thrombosis and infection. Several factors are associated with the formation and propagation of thrombosis and several studies have shown an association between central line thrombosis and infection.
QuESTIon
In a population of acute hospital patients with central venous catheters, does the use of heparinbonded central venous catheters compared with non-heparin-bonded control catheters reduce the incidence of complications?
1. Heparin-bonded CVCs reduce the incidence of catheter-related thrombosis and infection in children and adults. 2. The local incidence of catheter-related thrombosis and infection (and their related costs) and the cost of heparin-bonded catheters need to be considered in a cost-benefit analysis.
LITErATurE SEArCH
Initial search terms included: (heparin AnD bonded), (access or catheter or device or line)
The databases searched included: CInAHL, MEDLInE, Cochrane Library, Embase.
The database searched for unpublished studies was: ProQuest Digital Dissertation.
The search terms used for each specific database are listed below:
CInAHL ( Embase (1974-present): (heparin-bond* or heparin bond*), explode central-venous-catheter*, (catheter* or device* or line*) Digital Dissertations: (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) : (heparin bond* or heparin-bond*), (catheter* or device* or line*) using these search strategies, only two studies were identified in children 1, 2 and a single study of heparinbonded catheters in adults 3 . one of the two studies in children was excluded because it did not fulfill the criteria of a randomized controlled trial 1 . Pierce, Wade and Mok was therefore the only article included in this appraisal 2 .
CrITICAL APPrAISAL
Pierce, Wade and Mok 2 1. The assignment of the patients to the treatment/ control groups was achieved by selecting consecutive randomly numbered opaque envelopes. 2. All patients who entered the trial were properly accounted for at the study's conclusion. All patients were analysed in the groups to which they were randomized. 3. The principal investigator, radiologist and microbiologist were all blinded to the type of catheter. 4. The Hospital Ethics Committee approved the study and signed parental consent was obtained. 5. Both treatment and control groups were similar at the start of the trial, including age, gender, size of catheter, site of insertion, number of days of line in situ, inotrope usage, administration of TPn and blood and final diagnosis. 6. Both groups were treated equally, aside from the experimental intervention. Venous thrombosis was examined by colour Doppler ultrasound within three days of insertion and then at 3-day intervals until the CVC was removed. Blood cultures were taken from the CVC and one other site on insertion and then at three-day intervals until removal of the CVC.
Applegren et al 3 1. The assignment of the patients to the treatment/ control groups was randomized but the method was not explicitly stated. 2. A total of 55 catheters were randomized; however, 14/27 heparinized and 9/28 control catheters were excluded due to insertion difficulty or removal out of hours without culture. 3. The study was double-blinded but the method was not detailed. 4. The hospital Ethics Committee approved the study and informed consent was obtained. 5. The study groups had similar demographics (age, sex, diagnosis, body mass index) and there was no difference in insertion site, catheter insertion difficulty, reason for use, or length of insertion time between the two groups. 6. Both groups were treated equally aside from the experimental intervention. All catheters were inserted by an anaesthetist in the intensive care unit either into the jugular or subclavian vein using a standardized technique. 7. The catheters were removed for the following clinical indications: (1) no longer required or (2) mechanical failure or (3) The prevention or reduction in the occurrence of CVC-associated thrombosis and infection are important management goals. CVC complications significantly increase patient morbidity and cost per patient care episode. In the case of thrombosis there is a need for therapeutic anticoagulation for at least six to twelve weeks. Also there is the potential for persistent anatomical deformity of the venous system that may predispose to further thrombotic events or result in a post-phlebitic syndrome with an associated risk of mortality. In selected patients with congenital heart disease such as those with single ventricle pathology, central venous thrombosis may compromise future surgical options. In the study presented the use of heparin-bonded catheters demonstrated a reduction in the risk for thrombosis. other randomized studies assessing low dose heparin infusions (100 Iu/kg/day) have also shown significant reduction in line-associated thrombosis rates without significant increase in serious bleeding and may be an alternative and potentially less expensive strategy. Small studies of prophylactic dose low molecular weight heparin and mini-dose warfarin have not demonstrated a clear benefit to date.
Dr Mark Hayden, Royal Children's Hospital, Brisbane: Central venous catheter-related complications are a significant issue in the paediatric intensive care unit. Thrombosis and infection appear to interact synergistically. Strategies to reduce these complications include: (1) sterile insertion and access, (2) inserting the line in a larger vessel (i.e. SVC or internal jugular vein), (3) heparin-bonding and (4) antibiotic-coating. A recent article on antiboticcoated lines demonstrated an increase in fungal infection 5 . The study analysed here was of a high standard. unfortunately, there are no other studies of similar quality to confirm their findings. However, the evidence presented here suggests that we should consider routine use of heparin-bonded lines. 
